UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1), p.549

2023

Volltextzugriff (PDF)

Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?

Israel journal of health policy research, 2017-12, Vol.6 (1), p.49-49, Article 49

2017

Volltextzugriff (PDF)

Rare coexistence of Rosai-Dorfman disease and nodal marginal zone lymphoma complicated by severe life-threatening autoimmune hemolytic anemia

Leukemia & lymphoma, 2013-07, Vol.54 (7), p.1553-1556

2013

Volltextzugriff (PDF)

A Puzzling "Switch" in Blood Type Following Blood Transfusion

Annals of Laboratory Medicine, 2017, 37(3), , pp.293-295

2017

Volltextzugriff (PDF)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

The New England journal of medicine, 2019-05, Vol.380 (22), p.2104-2115

2019

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

Educating the educator about patient blood management

Transfusion and apheresis science, 2022-08, Vol.61 (4), p.103397-103397, Article 103397

2022

Volltextzugriff (PDF)

Can Blood Inflammatory Markers Identify Pregnant Women with Preeclampsia? Still a Controversial Issue

The Israel Medical Association journal, 2024-09, Vol.26 (8), p.500

2024

Volltextzugriff (PDF)

Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel

Leukemia & lymphoma, 2023-12, Vol.64 (13), p.2148-2155

2023

Volltextzugriff (PDF)

Can an Anemic Patient Be a Partner to Treatment Decision-Making?

The Israel Medical Association journal, 2023-11, Vol.25 (11), p.766-768

2023

Volltextzugriff (PDF)

The Involvement of LAG-3[sup.positive] Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1)

2023

Volltextzugriff (PDF)

Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma

Leukemia research, 2020-12, Vol.99, p.106476, Article 106476

2020

Volltextzugriff (PDF)

Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation

Experimental hematology, 2018-07, Vol.63, p.17-21.e1

2018

Volltextzugriff (PDF)

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

Blood, 2018-11, Vol.132 (Supplement 1), p.5076-5076

2018

Volltextzugriff (PDF)

The role of blood inflammatory markers in the preoperative diagnosis of acute appendicitis

International journal of laboratory hematology, 2024-02, Vol.46 (1), p.58-62

2024

Volltextzugriff (PDF)

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

The New England journal of medicine, 2024-08, Vol.391 (5), p.408-421

2024

Volltextzugriff (PDF)

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Blood, 2016-12, Vol.128 (22), p.5562-5562

2016

Volltextzugriff (PDF)

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

British journal of haematology, 2016-01, Vol.172 (1), p.89-96

2016

Volltextzugriff (PDF)

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

The Lancet. Haematology, 2022-02, Vol.9 (2), p.e98-e110

2022

Volltextzugriff (PDF)

Bortezomib‐induced peripheral neuropathy is related to altered levels of brain‐derived neurotrophic factor in the peripheral blood of patients with multiple myeloma

British journal of haematology, 2014-02, Vol.164 (3), p.454-456

2014

Volltextzugriff (PDF)

The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma

International journal of molecular sciences, 2023-12, Vol.25 (1)

2023

Volltextzugriff (PDF)

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Blood, 2018-11, Vol.132 (Supplement 1), p.3259-3259

2018

Volltextzugriff (PDF)

Treatment patterns and clinical outcomes in high‐risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi‐center retrospective study

American journal of hematology, 2018-06, Vol.93 (6), p.810-815

2018

Volltextzugriff (PDF)

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.2252-2252

2014

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(39)
Berichte
(2)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(16)
Hematology
(15)
Aged
(11)
Male
(11)
Multiple Myeloma
(11)
Middle Aged
(10)
Female
(9)
Multiple Myeloma - Drug Therapy
(7)
Retrospective Studies
(7)
Oncology
(6)
Adult
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Bortezomib
(5)
Dexamethasone - Administration & Dosage
(5)
General & Internal Medicine
(5)
Medicine, General & Internal
(5)
Treatment Outcome
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma

Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?

Rare coexistence of Rosai-Dorfman disease and nodal marginal zone lymphoma complicated by severe life-threatening autoimmune hemolytic anemia

A Puzzling "Switch" in Blood Type Following Blood Transfusion

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Educating the educator about patient blood management

Can Blood Inflammatory Markers Identify Pregnant Women with Preeclampsia? Still a Controversial Issue

Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel

Can an Anemic Patient Be a Partner to Treatment Decision-Making?

The Involvement of LAG-3[sup.positive] Plasma Cells in the Development of Multiple Myeloma

Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma

Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation

Tissue Molecular Genotyping Improves Patient Blood Management in Syrian Injured Patients Treated in Israel

The role of blood inflammatory markers in the preoperative diagnosis of acute appendicitis

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Bortezomib‐induced peripheral neuropathy is related to altered levels of brain‐derived neurotrophic factor in the peripheral blood of patients with multiple myeloma

The Involvement of LAG-3 positive Plasma Cells in the Development of Multiple Myeloma

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Treatment patterns and clinical outcomes in high‐risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi‐center retrospective study

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Suchergebnisse filtern